You’re cruising through a Q-bank block when a “simple” diuretic question suddenly turns into a minefield of potassium, aldosterone, acid–base, and drug interactions. The trick with K-sparing diuretics isn’t just knowing what they are—it’s knowing why every other answer choice is wrong in this patient.
Tag: Cardiovascular > Cardiac Pharmacology
The Vignette (Classic Q-bank Style)
A 67-year-old man with HFrEF (EF 30%) and hypertension is taking lisinopril and furosemide. He reports mild breast tenderness. Vitals are stable. Labs show:
- Na⁺ 138 mEq/L
- K⁺ 3.1 mEq/L
- HCO₃⁻ 33 mEq/L
- Creatinine 1.0 mg/dL
Which medication would most likely improve survival in this patient?
Answer choices:
A. Hydrochlorothiazide
B. Spironolactone
C. Acetazolamide
D. Amiloride
E. Mannitol
Step-by-Step: What the Stem Is Screaming
This stem gives you three huge clues:
- HFrEF (EF 30%) → certain drugs improve mortality (ACEi/ARB/ARNI, beta blocker, aldosterone antagonists, SGLT2 inhibitors)
- Loop diuretic + metabolic alkalosis + hypokalemia
- K⁺ 3.1 and HCO₃⁻ 33 → classic for loop diuretic effects
- Breast tenderness → points toward endocrine effects of spironolactone, but here it’s a subtle distractor: he’s not on it yet.
So you’re looking for a drug that:
- spares K⁺ (fixes hypokalemia), and
- improves survival in HFrEF
Correct Answer: B. Spironolactone
Why it’s correct
Spironolactone (and eplerenone) are aldosterone receptor antagonists in the collecting tubule.
High-yield mechanisms
- Aldosterone normally ↑ ENaC and ↑ Na⁺/K⁺-ATPase → Na⁺ reabsorption, K⁺ secretion, H⁺ secretion
- Blocking aldosterone →
- ↓ Na⁺ reabsorption
- ↓ K⁺ secretion (K-sparing)
- ↓ H⁺ secretion (can cause metabolic acidosis)
Why it improves survival in HFrEF
Aldosterone antagonists reduce:
- cardiac remodeling/fibrosis
- neurohormonal activation (RAAS-driven pathology)
This is why they’re not “just diuretics” in heart failure—they’re mortality meds.
Key adverse effects (USMLE favorites)
- Hyperkalemia (especially with ACEi/ARB, CKD)
- Metabolic acidosis (type 4 RTA-like physiology)
- Antiandrogen effects (spironolactone > eplerenone):
- gynecomastia, decreased libido, impotence, menstrual irregularities
Pearl: If the question wants “same benefit, fewer endocrine effects,” think eplerenone.
Fast Map: K-sparing Diuretics at a Glance
| Drug | Class | Site | Mechanism | Big Uses | Big Toxicities |
|---|---|---|---|---|---|
| Spironolactone | Aldosterone antagonist | Collecting tubule | Blocks aldosterone receptor → ↓ ENaC expression | HFrEF mortality benefit, hyperaldosteronism, cirrhosis ascites | HyperK, metabolic acidosis, gynecomastia |
| Eplerenone | Aldosterone antagonist | Collecting tubule | Same as above, more selective | HFrEF mortality benefit | HyperK (less gyno) |
| Amiloride | ENaC blocker | Collecting tubule | Blocks ENaC directly | Liddle syndrome, lithium-induced nephrogenic DI, K wasting from other diuretics | HyperK, metabolic acidosis |
| Triamterene | ENaC blocker | Collecting tubule | Blocks ENaC directly | Similar to amiloride | HyperK (± kidney stones in some refs) |
Now Kill the Distractors (Why Each Wrong Choice Matters)
A. Hydrochlorothiazide (Thiazide diuretic) — Wrong
Why students pick it: “Hypertension + diuretic = thiazide.”
Why it’s wrong here:
- Thiazides worsen hypokalemia: ↑ Na⁺ delivery to collecting duct → ↑ K⁺ secretion
- Thiazides can contribute to metabolic alkalosis (like loops)
- Most importantly: thiazides do not provide the classic mortality benefit in HFrEF the way aldosterone antagonists do
High-yield thiazide facts
- Site: DCT
- Blocks Na⁺/Cl⁻ cotransporter
- Causes: hyperGLUC (Hyperglycemia, HyperLipidemia, HyperUricemia, HyperCalcemia)
C. Acetazolamide (Carbonic anhydrase inhibitor) — Wrong
Why students pick it: They see alkalosis () and want to “fix it.”
Why it’s wrong here:
- Yes, acetazolamide causes bicarbonaturia → metabolic acidosis
- But it’s a weak diuretic and not a survival drug in HFrEF
- It also tends to cause hypokalemia (more Na⁺ delivered distally → K⁺ wasting)
High-yield uses
- Acute mountain sickness
- Idiopathic intracranial hypertension
- Glaucoma
- Metabolic alkalosis (sometimes used clinically), but Step-style questions usually want mechanism and side effects
High-yield toxicity
- Sulfa allergy
- Calcium phosphate stones (alkalinizes urine)
- Paresthesias
D. Amiloride (ENaC blocker) — Wrong (but tempting)
Why students pick it: It’s K-sparing and would help hypokalemia.
Why it’s still wrong:
- Amiloride spares K⁺—true.
- But it does not have the same hallmark mortality benefit in HFrEF that aldosterone antagonists do (that’s the board-style nuance).
- In this vignette, the question asks “most likely improve survival,” which points hard to spironolactone/eplerenone.
When amiloride is the best answer
- Liddle syndrome (hypertension + hypokalemic metabolic alkalosis with low renin/aldosterone)
- Lithium-induced nephrogenic DI (amiloride blocks lithium entry through ENaC)
- Add-on to thiazide/loop to blunt K wasting (symptom control, not mortality)
E. Mannitol (Osmotic diuretic) — Wrong
Why students pick it: They associate it with fluid removal.
Why it’s wrong here:
- Mannitol works in the proximal tubule and descending limb by increasing tubular osmoles
- It is used for:
- increased intracranial pressure
- increased intraocular pressure
- In heart failure, mannitol can worsen pulmonary edema by expanding intravascular volume early on
Board pearl: Mannitol is contraindicated in anuria and heart failure/pulmonary edema.
The Core Physiology Behind K-Sparing Diuretics (The “Why” You Keep Relearning)
Potassium secretion in the collecting duct is driven by:
- Na⁺ reabsorption via ENaC (creates a lumen-negative potential)
- Aldosterone signaling (upregulates ENaC and Na⁺/K⁺-ATPase)
- Increased distal Na⁺ delivery/flow (more substrate for ENaC)
So:
- Loops/thiazides → increase distal Na⁺ delivery → hypokalemia + metabolic alkalosis
- K-sparing diuretics (ENaC blockers or aldosterone antagonists) → reduce ENaC effect → hyperkalemia + metabolic acidosis
USMLE-Grade Takeaways (Memorize These)
- Spironolactone/eplerenone: K-sparing + mortality benefit in HFrEF
- Amiloride/triamterene: K-sparing, but think Liddle and lithium-induced nephrogenic DI
- K-sparing diuretics → hyperkalemia + metabolic acidosis
- Loops/thiazides → hypokalemia + metabolic alkalosis
- Spironolactone adverse effects: gynecomastia (use eplerenone if that’s the issue)
Quick Practice: One-Line Variant Questions
- “HF patient on ACE inhibitor develops K⁺ 6.2 after starting a new drug” → suspect spironolactone/eplerenone
- “Young patient with HTN, low renin/aldo, hypokalemia” → treat Liddle with amiloride
- “Bilateral pulmonary edema after a medication used for ICP” → mannitol